Saturday, December 16, 2023 3:07:09 PM
manibiotech,
The set up is as it is and it is legal. If you are invested then you may not like it but also know there is good will value to be had by Linda working closely with both Advent by keeping all tech in house and because Advent received development grants from the U.K. based on its independence from NWBO.
If the board of directors are not doing their job to protect all investors then challenge their independence if you want. Otherwise all you are spewing is sour grapes for whatever reason you care to point to or others might suggest. Obviously the rubber meets the road when a commercial scale contract services agreement is reached and THAT is where ALL NWBO investors need to be adequately represented and competitive bids from others need to be considered.
Perhaps you have a preemptive strategy you would like to suggest that keeps NWBO Linda negotiating honestly with Advent Linda. Then again, Merck or other might have their own strategy in play ; ). Best wishes.
The set up is as it is and it is legal. If you are invested then you may not like it but also know there is good will value to be had by Linda working closely with both Advent by keeping all tech in house and because Advent received development grants from the U.K. based on its independence from NWBO.
If the board of directors are not doing their job to protect all investors then challenge their independence if you want. Otherwise all you are spewing is sour grapes for whatever reason you care to point to or others might suggest. Obviously the rubber meets the road when a commercial scale contract services agreement is reached and THAT is where ALL NWBO investors need to be adequately represented and competitive bids from others need to be considered.
Perhaps you have a preemptive strategy you would like to suggest that keeps NWBO Linda negotiating honestly with Advent Linda. Then again, Merck or other might have their own strategy in play ; ). Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
